© Chronic kidney disease, defined as evidence of structural or functional renal impairment for 3 or more months, is generally progressive and irreversible, affecting multiple metabolic pathways. Altered protein and energy homeostasis, abnormal protein catabolism, acid–base derangements, and hormonal dysfunction ensue. Normal growth and development may be hindered, especially in children. Chronic kidney disease is categorized in stages, with symptoms that vary across the stages (see Box S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). However, as chronic kidney disease progresses, the accumulation of nitrogen-containing products from dietary and intrinsic protein catabolism may distort taste and smell and blunt appetite. Gastrointestinal nutrient absorption ultimately becomes abnormal, since uremia affects the microbiome and disrupts intestinal epithelia. Muscle and fat wasting may develop as kidney failure advances, exacerbated by coexisting conditions and frailty, particularly in elderly patients, who account for a large proportion of those who are affected. Hence, nutritional status often becomes disordered, and protein–energy wasting is common, requiring dietary adjustments in this population. Beyond dietary adjustments, however, nutritional therapy may help to manage uremia, as well as other complications such as electrolyte and acid–base imbalances, water and salt retention, mineral and bone disorders, and failure to thrive. In fact, dietary interventions may also be used for the conservative management of uremia or as a means of delaying or avoiding dialysis therapy, according to the patient’s preference. It is possible, though not yet unequivocally proved, that nutritional interventions slow disease progression independent of uremia management. Given that approximately 10% of the adult population worldwide has chronic kidney disease and considering the exceptionally high costs and burden of maintenance dialysis therapy and kidney transplantation, dietary interventions may be increasingly chosen as a management strategy for chronic kidney disease. This review considers several aspects of the nutritional management of chronic kidney disease in adults.

Role of Dietary Constituents in Kidney Disease

Protein

Whether the quantity or quality of ingested protein is a risk factor for incident kidney disease has been debated for nearly a century. Experimental evidence suggests that long-term dietary protein intake exceeding 1.5 g per kilogram of ideal body weight per day may cause glomerular hyperfiltration and proinflammatory gene expression, which are known risk factors for kidney disease, as in the diabetic nephropathy model. A high-protein diet, which is a popular weight-reduction strategy, has been shown to exacerbate proteinuria in persons with diabetes or...
hypertension, but its net effect on kidney health is unclear.

Why should the amount and type of protein intake influence the risk of chronic kidney disease? Animal models have shown that low-protein intake constricts the glomerular afferent arterioles and lowers intraglomerular pressure, whereas a high-protein diet dilates the afferent arterioles, which increases glomerular filtration. Over time, glomerular hyperfiltration itself may damage the remaining glomeruli. Thus, a low-protein diet has a preglomerular effect that may enhance the postglomerular effect of angiotensin-pathway modulators that dilate the efferent arterioles and consequently lower intraglomerular pressure (Fig. 1).

Findings from studies of dietary protein restriction in humans, however, have been less consistent. The Modification of Diet in Renal Disease (MDRD) study showed that the progression of kidney disease is only minimally decelerated by a low-protein diet, though several relevant factors, such as angiotensin-converting–enzyme inhibitors and angiotensin-receptor blockers, could have a synergistic effect. In contrast, a high-protein diet dilates the afferent arteriole and elevates intraglomerular pressure, leading to an increased glomerular filtration rate over a short period, but the glomerular hyperfiltration ultimately stimulates mesangial-cell signaling, leading to increased TGF-β release and subsequent progressive fibrosis and renal damage. CKD denotes chronic kidney disease.
vant limitations of the MDRD study, such as the relatively small sample and short follow-up time, should be noted (Table S1 and Fig. S1 in the Supplementary Appendix).13 Most other controlled trials have confirmed the beneficial effects of restricted protein intake (Table S2 in the Supplementary Appendix), as did several meta-analyses that included the MDRD study.14 Dietary protein sources may influence the outcome. A recent cohort study using a food-frequency questionnaire showed that a high intake of red and processed meat was associated with an increased risk of chronic kidney disease, whereas a lower risk was observed with a diet rich in nuts, legumes, and low-fat dairy products.15

Altogether, the current evidence suggests that a low-protein diet mitigates proteinuria in both experimental models5 and human kidney disease.16 The amelioration of proteinuria is probably related to the reduction in intraglomerular pressure (Fig. 1),11 which is a favorable effect that is independent of angiotensin-pathway modulation.11 Such a reduction in pressure also is relevant in any range of proteinuria17 and when kidney disease is in a relatively early stage, before the development of renal insufficiency, particularly in a patient who was previously consuming a high-protein diet.11,18

Restricting dietary protein also results in a proportional reduction in urea generation.19 After protein breakdown, individual amino acids are deaminated by removal of an α-amino group, leaving a carbon skeleton of ketoacids, which can be recycled to form other amino acids and proteins or can be used for energy generation through the tricarboxylic acid cycle,20 while urea is generated through the urea cycle (Fig. 2). A persistently high blood urea level, termed azotemia, which is a commonly used marker for uremia, may enhance protein carbamylation and generate reactive oxygen species, leading to oxidative stress, inflammation, endothelial dysfunction, and ultimately, cardiovascular disease.21 Ameliorating azotemia by reducing protein intake results in parallel reductions of other nitrogenous compounds that are thought to act as uremic toxins.22 Although uremic symptoms diminish by the consumption of less protein, only limited studies have examined the effectiveness and safety of a low-protein diet as a means of deferring or avoiding the transition to dialysis therapy.23,24

Of the various ranges of low protein intake (Table S3 and Fig. S2 in the Supplementary Appendix), 0.6 to 0.8 g per kilogram of body weight per day is the most frequently recommended target for adults with moderate-to-advanced kidney disease (estimated glomerular filtration rate [eGFR], <45 ml per minute per 1.73 m² of body-surface area) and for the management of substantial proteinuria (urinary protein excretion, >0.3 g per day). However, the so-called very-low-protein diet (<0.6 g of protein per kilogram per day), supplemented with essential amino acids or their ketoacids, is also used.25 People at increased risk for kidney disease, such as those who have undergone nephrectomy for kidney donation or for cancer treatment or who have diabetes mellitus or hypertension or polycystic kidneys, may benefit from modest protein intake (<1 g per kilogram per day) in order to maintain a moderately low intraglomerular pressure.26

The safety and feasibility of low protein intake are among the main concerns associated with a low-protein diet, along with the risk of protein–energy wasting and adherence to dietary restrictions (Table 1).27 For healthy persons, the recommended dietary allowance for protein is 0.8 g per kilogram per day, whereas 0.66 g per kilogram per day is the estimated average requirement for adults who have chronic kidney disease but are otherwise healthy. Hence, a diet consisting of 0.6 to 0.8 g of protein per kilogram per day fulfills dietary needs, especially if half the protein is of “high biologic value” (e.g., dairy products); the other half may be plant proteins. In clinical trials of low-protein diets administered at the lower threshold (0.6 g of protein per kilogram per day), deterioration of nutritional status has rarely, if ever, been reported.25 However, for most children, as well as adults who are at increased risk for malnutrition, protein intake closer to 0.8 g per kilogram per day may be necessary to ensure appropriate growth and development and to prevent or correct protein–energy wasting. The safety of and adherence to a low-protein diet can be improved by providing adequate energy (30 to 35 kcal per kilogram per day) and ongoing nutritional education and surveillance.28,29

SODIUM AND FLUIDS
The association between dietary sodium intake and blood pressure is most pronounced in persons who consume a high-sodium diet (>4 g of
Figure 2. Pathways Involved in Protein and Amino Acid Metabolism in Chronic Kidney Disease.

The tricarboxylic acid (TCA) cycle comprises a series of chemical reactions that can metabolize amino acids. Amino groups are the products of amino acid deamination. Urea is synthesized through the urea cycle in the liver from the oxidation of amino acids or from ammonia. These mechanisms serve to trap and neutralize the highly volatile and toxic ammonia that is released from α-amino groups on transamination of amino acids in the liver. (Fig. S2 in the Supplementary Appendix provides more details on the intestinal tract.) Acetyl-CoA denotes acetyl–coenzyme A.
**Table 1. Potential Benefits and Challenges of a Low-Protein Diet (LPD) in the Nutritional Management of Chronic Kidney Disease (CKD).**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Potential Benefits of LPD</th>
<th>Challenges and Risks of LPD</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD progression</td>
<td>Synergistic effect with angiotensin-pathway modulators to lower intraglomerular pressure†</td>
<td>In first several months, slight drop in GFR may be observed, as shown in MDRD study§</td>
<td>Inconclusive results in MDRD study, but small effect size in meta-analyses‡</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>Consistent antiproteinuric effect, which may mitigate hypoalbuminemia</td>
<td>LPD is contrary to notion that DPI must be increased to replace urinary protein loss</td>
<td>Some data suggest that even larger effect may be achieved with DPI of &lt;0.6 g/kg/day</td>
</tr>
<tr>
<td>Uremia management and deferral of dialysis</td>
<td>Supported by consistent and biologically plausible data for almost a century</td>
<td>Unlikely to worsen uremia but potential risk of resurfacing or exacerbating PEW</td>
<td>Patients at increased risk for PEW may benefit from supplements (e.g., EAA or KA)</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>H⁺ generation decreased in proportion to reduction in DPI, especially with larger proportion of plant-based food</td>
<td>The need for &gt;50% HBV protein may prompt higher intake of non–plant-based foods that are more acidogenic</td>
<td>Although &gt;50% HBV protein is recommended, the remainder can be from plant-based foods</td>
</tr>
<tr>
<td>Mineral and bone disease</td>
<td>The lower phosphorus content of LPD improves measures of mineral bone disease, including sHPT and high FGF-23</td>
<td>Higher calcium content in some KA preparations may increase calcium load</td>
<td>Additional improvements in bone health are possible by alleviating acidosis</td>
</tr>
<tr>
<td>PEW</td>
<td>Ameliorating hypoaalbuminemia in patients with proteinuria may help neutralize circulating inflammatory compounds</td>
<td>Weight loss may occur; the habit of LPD intake may continue after starting thrice-weekly hemodialysis, when higher protein intake is recommended</td>
<td>Half of dietary protein source should be HBV protein; liberalize diet during correction of PEW</td>
</tr>
<tr>
<td>Cardiovascular and metabolic health</td>
<td>Lower protein intake is associated with lower dietary salt and saturated fat intake and may be less atherogenic, given higher proportion of plant-based food</td>
<td>Higher dietary fat intake (to achieve DEI of 30–35 kcal/kg/day) may confound the goal of achieving a heart-healthy diet</td>
<td>Higher proportions of unsaturated fat and complex carbohydrates recommended</td>
</tr>
<tr>
<td>Glycemic control and insulin response</td>
<td>Improvement in insulin resistance is likely with LPD or VLPD, higher carbohydrate and fat intake (to achieve DEI 30–35 kcal/kg/day) may worsen glycemic control</td>
<td>Given increased insulin half-life and “burnt-out diabetes” with CKD progression, preventing hypo-glycemic episodes is prudent</td>
<td></td>
</tr>
<tr>
<td>Quality of life and adherence to LPD</td>
<td>Enhanced patient-centeredness, given that many patients seek nutritional therapies and dietary advice</td>
<td>Challenges with adherence; diet fatigue, poor palatability, and cravings reported</td>
<td>Recommend creative recipes and strategies to engage patients</td>
</tr>
<tr>
<td>Mortality</td>
<td>There are no convincing data to suggest reduced mortality, although dialysis deferral is a potential mechanism, given high mortality during early dialysis</td>
<td>Increased mortality highly unlikely with DPI of 0.6–0.8 g/kg/day unless severe PEW emerges and is uncorrected</td>
<td>Consider supplements or other corrective strategies whenever PEW is suspected or diagnosed</td>
</tr>
<tr>
<td>Hypertension management</td>
<td>MDRD and other data suggest improved BP control</td>
<td>Reduction in BP is more likely a result of concomitant lower salt intake than of LPD itself</td>
<td>Higher potassium intake from more plant-based foods may be a potential mechanism</td>
</tr>
<tr>
<td>Microbiome modulation</td>
<td>Improved microbiome profile may be achieved through reduced uremic toxin generation</td>
<td>Possibility of promoting unfavorable microbiome milieu cannot be excluded</td>
<td>Uremia itself can lead to unfavorable microbiome</td>
</tr>
</tbody>
</table>

* A diet that provides 0.6 to 0.8 g of protein per kilogram of body weight per day is recommended most frequently. BP denotes blood pressure, DEI dietary energy intake, DPI dietary protein intake, EAA essential amino acids, FGF-23 fibroblast growth factor 23, GFR glomerular filtration rate, HBV high biologic value, KA ketoacids, MDRD Modification of Diet in Renal Disease, PEW protein–energy wasting, sHPT secondary hyperparathyroidism, and VLPD very-low-protein diet.
† Angiotensin-pathway modulators include angiotensin-converting–enzyme inhibitors and angiotensin-receptor blockers. See Tables S4 and S5 and Box S2 in the Supplementary Appendix for additional data and examples of meals.
‡ The MDRD study data were originally presented by Klahr et al., with an additional analysis by Levey et al.
§ A meta-analysis by Kasiske et al. showed a significant but rather small effect size of an LPD in slowing the CKD progression rate.
sodium per day), have underlying hypertension, or are over the age of 55 years. In patients with established chronic kidney disease, dietary sodium restriction is invariably recommended to control fluid retention and hypertension and to improve the cardiovascular risk profile. However, it is not clear that dietary sodium chloride restriction can slow the progression of established kidney disease. Since cardiovascular trials involving dietary sodium restriction often exclude patients with renal disease, there are limited relevant interventional data for such patients. A reduced sodium intake enhances the effects of a low-protein diet and angiotensin-modulation therapy in decreasing intraglomerular pressure (Fig. 1) and may also decrease proteinuria and slow the progression of kidney disease.

Observational studies using urinary sodium excretion as a surrogate for sodium chloride intake have yielded inconsistent data, with some studies showing no association between dietary sodium intake and renal disease progression and others showing a positive association. A longitudinal study published in 2016, which involved serial 24-hour urine collections from 3939 patients with chronic kidney disease, suggested that the highest quartile of urinary sodium excretion (24.5 g per day), as compared with the lowest quartile (<2.7 g per day), was associated with 45% higher mortality and a 54% higher risk of disease progression. Incrementally worse cardiovascular outcomes were observed when dietary sodium intake exceeded 4 g per day. Observations in the general population suggest a J-shaped association; dietary sodium intake that is higher than 5 g per day and intake that is lower than 3 g per day are each associated with an increased risk of cardiovascular disease and death. Although a daily dietary allowance of less than 2.3 g of sodium (<100 mmol) is often recommended for patients with cardiovascular disease, there is no evidence that patients with kidney disease will benefit from this very low level of sodium restriction. Therefore, a daily dietary sodium intake of less than 4 g (<174 mmol) is recommended for the overall management of chronic kidney disease and its associated risks, with a sodium intake of less than 3 g (<131 mmol) for the specific management of symptomatic fluid retention or proteinuria. Evidence supporting a sodium intake of less than 1.5 g per day (<87 mmol per day) for patients with renal insufficiency is lacking, given the risk of hyponatremia and adverse outcomes, and patients with certain conditions, such as salt-losing nephropathies, should not be subjected to such stringent sodium restriction (Table 2).

Whereas adequate fluid intake may mitigate the risk of kidney disease, patients with renal insufficiency generally have polyuria. This is the basis for the recommendation that patients with stage 3 chronic kidney disease limit fluid intake to less than 1.5 liters per day in order to avoid hyponatremia; adjustment of that limit for a hot climate and other conditions associated with high insensible fluid losses is imperative. Adjunctive therapy with loop diuretics is often prescribed, particularly for patients who tend to have symptomatic fluid retention or hyponatremia, given the association of such conditions in chronic kidney disease with poor outcomes.

**Potassium**

Many potassium-rich foods, such as fresh fruits and vegetables, are considered healthy choices for most people, given the high fiber and vitamin content and low acidogenicity of such foods. In some large population cohorts at high risk for cardiovascular disease or diabetes, higher urinary potassium excretion is associated with a lower likelihood of all renal complications except for hyperkalemia. Given the well-established association of higher dietary potassium with lower urinary potassium levels (<4.0 mmol per liter) and high levels (>5.5 mmol per liter) are associated with more rapid kidney disease progression. Among patients with very advanced chronic kidney disease, the highest quartile of dietary potassium intake, as compared with the lowest quartile, is associated with an increase in the risk of death by a factor of 2.4; the association is independent of the plasma potassium level and other nutritional measures. In epidemiologic studies, both moderately low plasma potassium levels (<4.0 mmol per liter) and high levels (>5.5 mmol per liter) are associated with more rapid kidney disease progression. Dietary potassium restriction is often recommended in patients with hyperkalemia, especially those with more advanced stages of kidney disease.
### Table 2. Recommended Dietary and Nutrient Intake in Adults, According to the CKD Stage.*

<table>
<thead>
<tr>
<th>Dietary Constituent</th>
<th>Normal Kidney Function with Increased CKD Risk</th>
<th>Mild-to-Moderate CKD†</th>
<th>Advanced CKD‡</th>
<th>Transition to Dialysis‡</th>
<th>Ongoing Dialysis or Any Stage with Existing or Imminent PEW</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protein (g/kg/day)</strong></td>
<td>&lt;1.0; increase proportion of plant-based proteins</td>
<td>&lt;1.0 (consider 0.6–0.8 if eGFR &lt;45 ml/min/1.73 m² or rapid progression)</td>
<td>0.6–0.8, including 50% HBV protein, or &lt;0.6 with addition of EAA or KA</td>
<td>0.6–0.8 on nondialysis days and &gt;1.0 on dialysis days</td>
<td>1.2–1.4; may require &gt;1.5 if hypercatabolic state develops</td>
</tr>
<tr>
<td><strong>Sodium (g/day)‡‡</strong></td>
<td>&lt;4 (&lt;3 in patients with hypertension)§§</td>
<td>&lt;4; avoid intake of &lt;1.5 if hypernatremia likely</td>
<td>&lt;3; avoid intake of &lt;1.5 if hypernatremia likely</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
<tr>
<td><strong>Potassium (g/day)¶¶</strong></td>
<td>4.7 (same as recommended for general population)</td>
<td>4.7 unless frequent or severe hyperkalemia excursions likely</td>
<td>&lt;3 if hyperkalemia occurs frequently during high-fiber intake</td>
<td>&lt;3 if hyperkalemia occurs frequently during high-fiber intake</td>
<td>&lt;3; target high-fiber intake</td>
</tr>
<tr>
<td><strong>Phosphorus (mg/day)‖‖</strong></td>
<td>&lt;1000; minimize added inorganic phosphorus in preserved and processed foods</td>
<td>&lt;800; minimize added inorganic phosphorus and encourage consumption of more plant-based foods</td>
<td>&lt;800; minimize added inorganic phosphorus and encourage consumption of more plant-based foods</td>
<td>&lt;800; minimize added inorganic phosphorus; consider phosphorus binder</td>
<td>&lt;800; minimize added inorganic phosphorus; add phosphorus binder as needed</td>
</tr>
<tr>
<td><strong>Calcium (mg/day)</strong></td>
<td>1000–1300 (adjusted for age)</td>
<td>800–1000</td>
<td>800–1000</td>
<td>800–1000 or less</td>
<td>&lt;800</td>
</tr>
<tr>
<td><strong>Fibers, alkali, and plant-based foods (g/day)</strong></td>
<td>25–30; target higher proportion (&gt;50%) of plant-based foods (e.g., DASH diet)</td>
<td>25–30 or more; consider &gt;70% of plant-based foods</td>
<td>25–30 or more; consider &gt;70% of plant-based foods</td>
<td>25–30 or more; suggest avoiding strict vegan diet</td>
<td></td>
</tr>
<tr>
<td><strong>Energy (kcal/kg/day)</strong></td>
<td>30–35; adjust to target weight reduction if BMI &gt;30††</td>
<td>30–35; increase proportion with LPD</td>
<td>30–35; increase proportion with LPD</td>
<td>30–35; target higher intake if PEW present or imminent</td>
<td></td>
</tr>
<tr>
<td><strong>Fats</strong></td>
<td>Mostly monounsaturated and polyunsaturated lipids, including n–3 fatty acids</td>
<td>Mostly monounsaturated and polyunsaturated lipids, including n–3 fatty acids; increase proportion with low-protein intake</td>
<td>Mostly monounsaturated and polyunsaturated lipids, including n–3 fatty acids; increase proportion with low-protein intake</td>
<td>Mostly monounsaturated and polyunsaturated lipids, including n–3 fatty acids</td>
<td></td>
</tr>
</tbody>
</table>

* Normal kidney function is defined as an estimated GFR (eGFR) of at least 60 ml per minute per 1.73 m² of body-surface area. Patients in this category do not have substantial proteinuria but are at increased risk for CKD because of another condition (e.g., diabetes, hypertension, or polycystic kidney) or a solitary kidney. (A solitary kidney can be a congenital or acquired state, with the latter due to nephrectomy for donation or cancer treatment.) Mild-to-moderate CKD is defined as an eGFR of 30 to less than 60 ml per minute per 1.73 m² without substantial proteinuria (<0.3 g of protein per day). Patients with advanced CKD have an eGFR of less than 30 ml per minute per 1.73 m² or substantial proteinuria (>0.3 g per day). Patients transitioning to dialysis therapy usually have good residual kidney function. Protein-energy wasting (PEW) is defined according to the criteria of the International Society of Renal Nutrition and Metabolism. In the denominator of the dietary recommendations for protein and energy, kg denotes the ideal body weight (IBW), especially for persons with a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) above 30. The IBW can be estimated in males as 50.0 kg + 2.3 kg for each inch over 5 ft, and in females as 45.5 kg + 2.3 kg for each inch over 5 ft. To convert phosphorus to millimoles per day, multiply by 0.02495. DASH denotes Dietary Approaches to Stop Hypertension.† Kidney-transplant recipients may have an eGFR of 30 to less than 60 ml per minute per 1.73 m² or less than 30 ml per minute per 1.73 m² or may be transitioning to dialysis; the transition-to-dialysis stage includes incremental dialysis preparation. These three subgroups of patients can be approached similarly with respect to dietary management.‡ Patients with certain conditions such as salt-losing nephropathies should not be subjected to sodium restriction.‡‡ For patients with heart failure, the American Heart Association recommends no more than 2.3 g of sodium per day (equivalent to 1 teaspoon of salt) and suggests an ideal limit of 1.5 g of sodium per day (https://sodiumbreakup.heart.org/how_much_sodium_should_i_eat).§§ Patients who are undergoing peritoneal dialysis and have hypokalemia should have a goal of increasing their potassium intake.¶¶ Dietary phosphorus should be restricted regardless of the patient's status with respect to hyperphosphatemia.‖‖ Carbohydrates, which provide 40 to 60% of the daily energy intake, should be natural (nonrefined) and complex with a high-fiber content.†† In obese patients, lower energy ranges can be targeted. Table S5 in the Supplementary Appendix provides recommendations for vitamin D, other vitamins, trace elements, management of weight and cardiovascular risks, and fluid management.
kidney disease. However, excessive dietary restrictions can expose patients to less heart-healthy and more atherogenic diets and worsen constipation, which may actually result in higher gut potassium absorption. Despite a higher risk of hyperkalemia with the progression of kidney disease, few studies have examined the effects of dietary potassium restriction or methods of extracting potassium during food preparation and cooking. It is not clear whether potassium-binding agents can allow liberalization of dietary potassium intake with the inclusion of healthier potassium-rich foods. In patients with a tendency toward hyperkalemia (>5.5 mmol of potassium per liter), a dietary potassium intake of less than 3 g per day (<77 mmol per day) is recommended, with the stipulation that a balanced intake of fresh fruits and vegetables with high fiber should not be compromised (Table 2).

PHOSPHORUS

In the general population, higher plasma phosphorus levels have been associated with an increased risk of incident kidney disease. Overt hyperphosphatemia is infrequent in stages 1, 2, and 3 of chronic kidney disease, given the high circulating and tissue levels of parathyroid hormone and fibroblast growth factor 23 (FGF-23) in renal insufficiency, which promote urinary phosphorus excretion. Elevated parathyroid hormone and FGF-23 levels can cause renal bone disease, left ventricular hypertrophy, vascular calcification, and accelerated progression of kidney disease from vascular and tubulointerstitial injury (Fig. 2), highlighting the importance of dietary phosphorus management, even in patients without apparent hyperphosphatemia. Although a low-protein diet also decreases phosphorus intake, the quantity and bioavailability of phosphorus differ according to the type of protein. For instance, the phosphorus-to-protein ratio of egg whites and egg yolks (which have 3.6 and 2.7 g of protein per egg, respectively) is 1 to 2 mg and 20 to 30 mg per gram, respectively. The gastrointestinal absorption of phosphorus, mostly in the form of phytates, is lower from plants (along with fibers) than from meat (30 to 50% vs. 50 to 70%). Since food additives include readily absorbable inorganic phosphorus, ingestion of processed foods results in an even higher phosphorus burden (Table S4 in the Supplementary Appendix).

Restricting dietary phosphorus intake to less than 800 mg per day (26 mmol per day) is recommended for patients with moderate-to-advanced kidney disease, and processed foods with a high phosphorus-to-protein ratio should be minimized. However, in patients with stage 5 chronic kidney disease who receive dialysis therapy or who are at increased risk for protein–energy wasting, excessively stringent restriction of protein intake to control hyperphosphatemia may be associated with poor outcomes. Thus, an individualized dietary approach that incorporates ample use of phosphorus binders is optimal.

CALCIUM AND VITAMIN D

The renal insufficiency–associated decline in 1,25-dihydroxyvitamin D diminishes gastrointestinal absorption of calcium; however, passive diffusion of ionized calcium continues and may lead to a positive calcium balance, aggravated by diminished urinary calcium excretion due to secondary hyperparathyroidism. Increased calcium release from bone in hyperactive renal bone disease (increased bone resorption because of secondary hyperparathyroidism) enhances the positive calcium balance and may worsen vascular calcification. Gut calcium absorption varies because of differences in dissociation and bioavailability from one type of elemental calcium to another; for instance, calcium citrate is more readily absorbable than calcium acetate. Two studies suggested that an intake of 800 to 1000 mg of elemental calcium per day (20 to 25 mmol per day) can result in a stable calcium balance in people with stage 3 or 4 chronic kidney disease. Hence, whereas the suggested calcium intake for persons without kidney disease is 1000 to 1300 mg per day (25 to 32 mmol per day), in patients with moderate-to-advanced chronic kidney disease, 800 to 1000 mg of elemental calcium per day from all sources should suffice (Table 2).

Native vitamin D supplementation (cholecalciferol or ergocalciferol) may be offered to patients with chronic kidney disease in whom circulating vitamin D levels have been documented as low. In some studies, vitamin D analogues have been associated with decreased proteinuria in addition to healing of renal osteodystrophy. Notwithstanding inconsistent data on the requirement and effect of vitamin D in certain subpopulations of patients with chronic kidney disease,
including black Americans, who have lower total vitamin D levels and higher parathyroid hormone levels than white Americans, hydroxylated vitamin D agents may be needed in addition to native vitamin D to control progressive secondary hyperparathyroidism.

Nutritional Management of Chronic Kidney Disease

including the use of absorbent ingestible agents and high-fiber or vegetarian diets, are being tested as a means of reducing gut absorption of uremic toxins in order to control uremic symptoms and slow disease progression.

Vegetarian Diet, Fiber, and the Microbiome

Comparisons of data from populations with largely vegetarian diets and data from populations with meat-based diets do not clearly distinguish a difference in the risk of kidney disease between plant-based and animal-based protein. Plant-based foods are recommended as part of many strategies for the prevention and management of kidney disease, since these foods contain smaller amounts of saturated fatty acids, protein, and absorbable phosphorus than meat, generate less acid, and are rich in fibers, polyunsaturated and monounsaturated fatty acids, magnesium, potassium, and iron. In patients with chronic kidney disease, a diet with a higher proportion of plant sources (>50%) has been associated with better outcomes. Constipation can lead to higher retention of uremic toxins and hyperkalemia, whereas loosening stools may enhance fluid loss and removal of nitrogenous products. The protein in a vegetarian diet is less fermentable and has high fiber content, increasing peristalsis and the number of bowel movements, and is associated with less uremic toxin production, exposure, and absorption.

Uremia itself, as well as dietary restrictions and pharmacotherapy, including antibiotics, may alter the gut microbiome, and this change may have a bearing on the symptoms and progression of kidney disease (Fig. S3 in the Supplementary Appendix). Microbiome modulation through dietary interventions such as probiotics may offer an opportunity to control the production, degradation, and absorption of certain uremic toxins that are fermentation by-products of gut microbial activities, including indoxyl sulfate, p-cresol, and trimethylamine. As an example, in a study involving 40 patients with moderate-to-advanced chronic kidney disease, a lower ratio of dietary fiber to protein was associated with higher blood levels of indoxyl sulfate and p-cresol. Nutritional and pharmacologic interventions, Unrefined carbohydrates account for half the usual daily energy intake, and the proportion may be even higher with a low-protein diet. In patients with kidney disease, carbohydrates should be complexed with high fiber content (e.g., whole-wheat breads, multigrain cereal, oatmeal, and mixed fruits and vegetables) to help reduce dietary phosphorus and protein as well as urea and creatinine generation. Such a diet is thought to promote a more favorable microbiome with less constipation. Nonsaturated fat is the preferred lipid in the diet. Replacement of butter with flaxseed, canola, or olive oil, all of which are rich in n-3 fatty acids, may be worthwhile. For example, a recent study suggested that dietary n-3 fatty acid supplementation in patients with diabetes and hypertriglyceridemia may reduce albuminuria and preserve renal function. There is currently no evidence that low-fat diets, recommended by some guidelines, improve kidney disease outcomes. In a low-protein diet, fat and carbohydrate should together account for more than 90% of the daily energy intake requirement of 30 to 35 kcal per kilogram to avoid protein–energy wasting. Obviously, in patients with diabetic kidney disease, proper glycemic control should be maintained, but adequate energy intake is needed to mitigate the risk of protein–energy wasting and hypoglycemia, which increases with worsening kidney function.

Dietary Management of Acidosis in Kidney Disease

Daily acid production results from bicarbonate losses in the gut (20 to 30 mmol of bicarbonate per day), breakdown of amino and nucleic acids from proteins (20 to 30 mmol per day), and oxidation of carbohydrates and fats to lactic acid and ketoacids (10 to 20 mmol per day). The kidneys regenerate the bicarbonate used for buffering by excretion of both net acid and acid.
buffers, including phosphate, and by ammoniagenesis through deamination of glutamine in the proximal tubule and its synthesis to ammonium in the collecting ducts, with subsequent urinary excretion (Fig. 2). Hence, kidney disorders, including renal tubular defects, are often associated with chronic metabolic acidosis, which leads to glucocorticoid overproduction with resultant muscle wasting, worsens uremia-associated insulin resistance, and increases parathyroid hormone release. An increase in the dietary acid load may be associated with glomerular hyperfiltration. Metabolic acidosis is associated with more rapid kidney disease progression and an increase in the overall risk of death. Hyperparathyroidism, along with chronic buffering of acid by bone, leads to progressive loss of bone mineral and worsening renal osteodystrophy. Hence, reduced protein intake with a greater proportion of diet from plant-based foods to correct acidosis improves bone mineralization and may slow protein breakdown and disease progression. Adjunctive alkali therapy can also be considered to mitigate acidosis in patients with chronic kidney disease.

**References**


**Practice Strategies**

Dietary protein, energy, and micronutrient intakes should be assessed regularly. Also, 24-hour urine collections should be performed to estimate dietary intakes of protein (based on urinary urea nitrogen), sodium, and potassium; to measure creatinine clearance and proteinuria; and to evaluate adherence to dietary recommendations, with suggestions for improving adherence if necessary (Fig. S4 in the Supplementary Appendix). Excessive restrictions may be harmful and should be avoided.

**Conclusions**

Given the high incidence and prevalence of chronic kidney disease and an urgent need for alternative disease management strategies, nutritional interventions with disease-specific dietary ranges that are patient-centered and cost-effective may help increase longevity and prolong the dialysis-free interval for millions of people worldwide. Additional studies are needed to ensure a more robust, evidence-based approach to the nutritional management of chronic kidney disease.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Dr. Connie M. Rhee for her review of an earlier version of this article and Ms. Vanessa Rojas-Bautista for assistance with the menu examples in the Supplementary Appendix.